A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931.
about
A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh-hant
name
A Comprehensive Safety Trial o ...... Oncology Group Study ANBL0931.
@en
A Comprehensive Safety Trial o ...... Oncology Group Study ANBL0931.
@nl
type
label
A Comprehensive Safety Trial o ...... Oncology Group Study ANBL0931.
@en
A Comprehensive Safety Trial o ...... Oncology Group Study ANBL0931.
@nl
prefLabel
A Comprehensive Safety Trial o ...... Oncology Group Study ANBL0931.
@en
A Comprehensive Safety Trial o ...... Oncology Group Study ANBL0931.
@nl
P2093
P2860
P50
P356
P1476
A Comprehensive Safety Trial o ...... Oncology Group Study ANBL0931.
@en
P2093
Andrew L Gilman
Arlene Naranjo
C Patrick Reynolds
John M Maris
Julie R Park
Karen S Messer
L Mary Smith
M Fevzi Ozkaynak
Marguerite Parisi
Mitchell B Diccianni
P2860
P356
10.3389/FIMMU.2018.01355
P577
2018-06-18T00:00:00Z